Alzheimer's Disease stem cell therapy — your questions answered (2026)
About stem cell therapy for Alzheimer's Disease
Alzheimer's disease is a progressive neurodegenerative disorder with complex amyloid, tau, inflammatory, vascular and synaptic biology. MSC, neural-cell and exosome proposals invoke anti-inflammatory, trophic or delivery mechanisms, but mechanistic plausibility does not show that an administered product reaches the brain or preserves cognition and daily function.
The evidence for Alzheimer's Disease
Human cell and exosome evidence remains investigational, product-specific and generally insufficient to establish clinical benefit. Biomarker movement cannot replace validated cognitive and functional outcomes, a comparator and adequate follow-up. The FDA patient page states that regenerative medicine therapies are not approved in the United States to treat Alzheimer's disease. Current established and approved options should be reviewed with a dementia specialist.
Do not compare a commercial cell or exosome package with approved dementia care using only headline price. Itemise diagnosis, product, route, imaging, travel, caregiver time, follow-up and complication care. Consider capacity, consent, financial vulnerability and the cost of delaying established assessment or treatment.
Is there a stem cell treatment for Alzheimer's?
Cell therapy for Alzheimer's Disease may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.
Which stage is eligible?
Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.
What outcomes are realistic?
Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.
Cost in the EU?
The partner-published indicative range for an Alzheimer's Disease programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Alzheimer's Disease (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
- Clinic perspective — Stem Plus on Alzheimer's Disease ↗
← Back to Alzheimer's Disease overview · Alzheimer's Disease cost →